TBPH Theravance Biopharma, Inc.

33.35
+1  (2%)
Previous Close 32.76
Open 32.81
Price To book 4.94
Market Cap 1.76B
Shares 52,855,000
Volume 221,253
Short Ratio 23.69
Av. Daily Volume 234,333

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved June 21, 2013.
VIBATIV (telavancin hydrochloride) for injection
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)
Approved April 30, 2015.
BREO ELLIPTA
Asthma
Phase 2a data due 2017.
TD-9855
nOH
Phase 3 study completion due 2018.
Closed Triple
Asthma
NDA filing submission announced November 21, 2016.
Closed Triple
COPD
Phase 3 trials met primary endpoint. 12 month safety trial data (mid-2017) and NDA filing end of 2017.
Revefenacin
COPD
Phase 2b initiated mid March 2015. Completion of study due mid-2017.
Velusetrag (TD-5108)
Gastroparesis
Phase 2 data released June 2016
TD-6450
Hepatitis C virus (HCV)
Phase 3 data due 2018
Telavancin
Bacteremia
Phase 3 first patient enrolled late February 2015. Data due 2017
Telavancin
Staphylococcus aureus bacteremia
Phase 3 data due in 2016
TD-4208
Chronic obstructive pulmonary disease (COPD

Latest News

  1. THERAVANCE BIOPHARMA, INC. Financials
  2. Theravance Biopharma, Inc. breached its 50 day moving average in a Bullish Manner : TBPH-US : March 6, 2017
  3. Theravance Biopharma, Inc. :TBPH-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017
  4. Theravance Biopharma, Inc. :TBPH-US: Earnings Analysis: 2016 By the Numbers : March 1, 2017
  5. THERAVANCE BIOPHARMA, INC. Files SEC form 10-K, Annual Report
  6. Theravance (TBPH) Q4 Loss Wider than Expected, Revenues Beat
  7. Edited Transcript of TBPH earnings conference call or presentation 27-Feb-17 10:00pm GMT
  8. Theravance Bio reports 4Q loss
  9. Theravance Bio reports 4Q loss
  10. THERAVANCE BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition
  11. Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  12. Q4 2016 Theravance Biopharma Inc Earnings Release - After Market Close
  13. Theravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : February 22, 2017
  14. Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
  15. Theravance Biopharma to Report Fourth Quarter and Full Year 2016 Financial Results on February 27, 2017
  16. Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
  17. Theravance Biopharma to Present at the Leerink Partners 6th Annual Global Healthcare Conference
  18. Theravance's Infection Drug Vibativ Positive in TOUR Study
  19. Theravance Biopharma, Inc. – Value Analysis (NASDAQ:TBPH) : January 23, 2017
  20. Theravance Biopharma Reports New Data from Ongoing TOUR™ Observational Patient Registry in Oral Presentation at SCCM Critical Care Congress